Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
Categories (click each to see list of all clinical trials associated with that category): Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: I/II (Cancer Control)
Principal Investigator: Holstein, Sarah
Eligibility: https://clinicaltrials.gov/study/NCT05177536?term=NCT05177536&rank=1
Summary
The primary objective is to estimate the proportion of subjects who are able to complete at least one year of maintenance therapy with iberdomide.
The secondary objectives include the following:
To estimate the median progression free survival (PFS)
To estimate the MRD-negativity rate at day 100, at one year post-initiation of maintenance therapy and at two years post-initiation of maintenance therapy
To estimate the sustained MRD-negativity rate (as defined as MRD negativity at study entry and at one year post-initiation of maintenance therapy)
To estimate the rate of conversion from MRD-positive (at study entry) to MRD-negative (at one year post-initiation of maintenance therapy)
To estimate overall survival (OS) distribution
To evaluate the safety profile, by reporting adverse events experienced by subjects, including development of second primary malignancies
Exploratory objective:
To evaluate changes in the peripheral blood immunophenotype during maintenance therapy